I 

116TH CONGRESS 

1ST SESSION H. R. 4667 

To amend the 21st Century Cures Act to reauthorize funding for NIH 

innovation projects, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

OCTOBER 11, 2019 

Ms. SHERRILL (for herself, Mr. LEVIN of California, and Ms. SPANBERGER) 

introduced the following bill; which was referred to the Committee on Energy and Commerce 

A BILL 

To amend the 21st Century Cures Act to reauthorize funding 

for NIH innovation projects, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Biomedical Innovation 

5 Expansion Act of 2019’’. 

6 SEC. 2. REAUTHORIZATION OF NIH INNOVATION PROJ7 ECTS. 

8 (a) TRANSFERS.—Section 1001(b)(2)(A) of the 21st 

9 Century Cures Act (Public Law 114–255) is amended by 


kjohnson on DSK79L0C42 with BILLS
2 

•HR 4667 IH

1 striking clauses (v) through (x) and inserting the fol2 lowing: 

3 ‘‘(v) For fiscal year 2021, 

4 $854,000,000. 

5 ‘‘(vi) For fiscal year 2022, 

6 $1,051,000,000. 

7 ‘‘(vii) For fiscal year 2023, 

8 $1,345,000,000. 

9 ‘‘(viii) For fiscal year 2024, 

10 $1,271,000,000. 

11 ‘‘(ix) For fiscal year 2025, 

12 $1,301,000,000. 

13 ‘‘(x) For fiscal year 2026, 

14 $1,306,000,000. 

15 ‘‘(xi) For fiscal year 2027, 

16 $1,336,000,000. 

17 ‘‘(xii) For fiscal year 2028, 

18 $1,376,000,000. 

19 ‘‘(xiii) For fiscal year 2029, 

20 $1,436,000,000. 

21 ‘‘(xiv) For fiscal year 2030, 

22 $1,469,000,000.’’. 

23 (b) AUTHORIZATION OF APPROPRIATIONS.—Section 

24 1001(b)(3)(A) of the 21st Century Cures Act (Public Law 


kjohnson on DSK79L0C42 with BILLS
3 

•HR 4667 IH

1 114–255) is amended by striking ‘‘2026’’ and inserting 

2 ‘‘2030’’. 

3 (c) OFFSETTING FUTURE APPROPRIATIONS.—Sec4 tion 1001(b)(3)(B) of the 21st Century Cures Act (Public 

5 Law 114–255) is amended by striking ‘‘2026’’ and insert6 ing ‘‘2030’’. 

7 (d) NIH INNOVATION PROJECTS.—Section 

8 1001(b)(4) of the 21st Century Cures Act (Public Law 

9 114–255) is amended— 

10 (1) in the matter preceding subparagraph (A), 

11 by striking ‘‘2026’’ and inserting ‘‘2030’’; 

12 (2) in subparagraph (A)— 

13 (A) in the matter preceding clause (i), by 

14 striking ‘‘$1,455,000,000’’ and inserting 

15 ‘‘$4,413,000,000’’; and 

16 (B) by striking clauses (v) through (x) and 

17 inserting the following: 

18 ‘‘(v) For fiscal year 2021, 

19 $209,000,000. 

20 ‘‘(vi) For fiscal year 2022, 

21 $300,000,000. 

22 ‘‘(vii) For fiscal year 2023, 

23 $419,000,000. 

24 ‘‘(viii) For each fiscal years 2024 

25 through 2030, $430,000,000.’’; 


kjohnson on DSK79L0C42 with BILLS
4 

•HR 4667 IH

1 (3) in subparagraph (B)— 

2 (A) in the matter preceding clause (i), by 

3 striking ‘‘$1,511,000,000’’ and inserting 

4 ‘‘$4,428,000,000’’; and 

5 (B) by striking clauses (v) through (x) and 

6 inserting the following: 

7 ‘‘(v) For fiscal year 2021, 

8 $250,000,000. 

9 ‘‘(vi) For fiscal year 2022, 

10 $302,000,000. 

11 ‘‘(vii) For fiscal year 2023, 

12 $450,000,000. 

13 ‘‘(viii) For each of fiscal years 2024, 

14 2025, and 2026, $400,000,000. 

15 ‘‘(ix) For fiscal year 2027, 

16 $425,000,000. 

17 ‘‘(x) For fiscal years 2028, 

18 $450,000,000. 

19 ‘‘(xi) For each of fiscal years 2029 

20 and 2030, $500,000,000.’’; 

21 (4) in subparagraph (C)— 

22 (A) in the matter preceding clause (i), by 

23 striking ‘‘$1,800,000,000’’ and inserting 

24 ‘‘$3,312,000,000’’; and 


kjohnson on DSK79L0C42 with BILLS
5 

•HR 4667 IH

1 (B) by amending clause (vii) to read as fol2 lows: 

3 ‘‘(vii) For each of fiscal years 2023 

4 through 2030, $216,000,000.’’; 

5 (5) in subparagraph (D)— 

6 (A) in the matter preceding clause (i), by 

7 striking ‘‘$30,000,000’’ and inserting 

8 ‘‘$250,000,000’’; and 

9 (B) by striking clause (iv) and inserting 

10 the following: 

11 ‘‘(iv) For each of fiscal years 2021, 

12 2022, and 2023, $50,000,000. 

13 ‘‘(v) For each of fiscal years 2024 

14 through 2030, $10,000,000.’’; and 

15 (6) by adding at the end the following: 

16 ‘‘(E) To support research related to com17 bating antimicrobial resistance and antibiotic 

18 resistant bacteria, not to exceed a total of 

19 $1,635,000,000, as follows: 

20 ‘‘(i) For fiscal year 2021, 

21 $100,000,000. 

22 ‘‘(ii) For each of fiscal years 2022 

23 through 2024, $150,000,000. 

24 ‘‘(iii) For each of fiscal years 2025 

25 through 2027, $175,000,000. 


kjohnson on DSK79L0C42 with BILLS
6 

•HR 4667 IH

1 ‘‘(iv) For each of fiscal years 2028 

2 and 2029, $180,000,000. 

3 ‘‘(v) For fiscal year 2030, 

4 $200,000,000. 

5 ‘‘(F) To support research and research ac6 tivities related to rare diseases or conditions, 

7 not to exceed a total of $758,000,000, as fol8 lows: 

9 ‘‘(i) For fiscal year 2021, 

10 $50,000,000. 

11 ‘‘(ii) For fiscal year 2022, 

12 $55,000,000. 

13 ‘‘(iii) For fiscal year 2023, 

14 $60,000,000. 

15 ‘‘(iv) For fiscal year 2024, 

16 $65,000,000. 

17 ‘‘(v) For fiscal year 2025, 

18 $70,000,000. 

19 ‘‘(vi) For fiscal year 2026, 

20 $75,000,000. 

21 ‘‘(vii) For fiscal year 2027, 

22 $80,000,000. 

23 ‘‘(viii) For fiscal year 2028, 

24 $90,000,000. 


kjohnson on DSK79L0C42 with BILLS
7 

•HR 4667 IH

1 ‘‘(ix) For fiscal year 2029, 

2 $100,000,000. 

3 ‘‘(x) For fiscal year 2030, 

4 $113,000,000.’’. 

5 (e) WORKPLAN.—Section 1001(c)(1)(A) of the 21st 

6 Century Cures Act (Public Law 114–255) is amended by 

7 striking ‘‘2026’’ and inserting ‘‘2030’’. 

8 (f) RECOMMENDATIONS.—Section 1001(c)(1)(C)(i) 

9 of the 21st Century Cures Act (Public Law 114–255) is 

10 amended by striking ‘‘2026’’ and inserting ‘‘2030’’. 

11 (g) ANNUAL REPORTS.—Section 1001(c)(2)(A) of 

12 the 21st Century Cures Act (Public Law 114–255) is 

13 amended by striking ‘‘2027’’ and inserting ‘‘2030’’. 

14 (h) SUNSET.—Section 1001(e) of the 21st Century 

15 Cures Act (Public Law 114–255) is amended by striking 

16 ‘‘September 30, 2026’’ and inserting ‘‘September 30, 

17 2030’’. 

Æ 


kjohnson on DSK79L0C42 with BILLS